Karyopharm Therapeutics (Nasdaq: KPTI) announced the initiation of its Phase 2 study of Selinexor (KPT-330) in patients with Richter's transformation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE